Hot Topics in PVD: New Drugs, New Trials Across the Spectrum of Pulmonary Hypertension in Heart and Lung Disease

20 February, 2024 3:00 p.m. to 4:00 p.m. EST

  • Committees and Communities
  • Education
  • Interdisciplinary Networks
  • Online Education
  • Past Webinars
  • Pulmonary Vascular Disease (PAH and CTEPH)
  • Webinar
Pulmonary Vascular Disease  Interdisciplinary Network Logo

This webinar will highlight new results from therapeutic studies of PAH, specifically Phase Two and Three Studies in Group 1 PAH, and will present information on new concepts for future PAH trials. Participants will learn the practical concerns for PAH RCT’s including sample size and study design as well as the relevance of primary and secondary endpoints to clinical practice and discuss any ethical issues.

Moderators

Helen Whitford, MBBS, FRACP
Marc Simon, MD, MS,

Presentations

Click any of the drop downs below to learn more about the specific talks being presented as part of this webinar.

New Results from Therapeutic Studies of PAH: Where We Have Been

Discussion of Phase Two and Three Studies of Sotatercept, Seralutinib, and Anastrazole for Group 1 PAH.

Presented by Clara Hjalmarsson, MD, PhD

Q&A Session

Led by Moderators

Practical Concerns and New Concepts for PAH Trials: How to Get There

This presentation will cover disease modification and how clinical trials can be designed to reflect mechanism. Participants will learn the practical concerns for PAH RCT’s including sample size and study design as well as the relevance of primary and secondary endpoints to clinical practice and ethical issues. Topics that will be covered in this area include target patient

Presented by Arun Jose, MD, MS

Q&A Session

Led by Moderators

Speakers